U.S. FTC sues Endo, Impax for 2017 agreement regarding pain drug
By Reuters Staff 2 Min Read WASHINGTON (Reuters) - The U.S. Federal Trade Commission said on Monday it has filed a lawsuit against Endo Pharmaceuticals and Impax Laboratories that alleges a 2017 agreement eliminated competition between the companies for the pain medicine oxymorphone ER. In addition to Endo Pharmaceuticals Inc and Impax Laboratories LLC, the lawsuit names as defendants Endo International Plc and Impax’s owner, Amneal Pharmaceuticals Inc, the agency said. The U.S. Food and Drug Administration had asked Endo in June 2017 to pull its extended-release oxymorphone product off the...